RxDoctor Payments Data

Lylian Hermann

Family · Milford, INNPI 1912636994

Payments from drug & device makers

$924in general payments, 2019–2025

Across 52 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$131
  • Novo Nordisk$116
  • Bayer$115
  • Xeris Pharmaceuticals, Inc.$107
  • Lilly USA, LLC$103
  • Exact Sciences$73
  • plus $279 from 9 others

What the payments were for

  • Food & beverage$90598%
  • Education$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$924 in reported general payments places this provider in the 65th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$53,685
Medicare patients
124
Services billed
888

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$39,452
JardianceEmpagliflozin34$37,473
TrulicityDulaglutide30$36,553
XareltoRivaroxaban13$21,248
EliquisApixaban17$16,760
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$16,172
JanuviaSitagliptin Phosphate13$11,047
AbrysvoRsv Vacc, Pref A And Pref B/Pf30$9,605
ShingrixVaricella-Zoster Ge/As01b/Pf34$7,498
FarxigaDapagliflozin Propanediol11$6,552
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$5,771
Novolog FlexpenInsulin Aspart15$3,095
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$2,749
Atorvastatin Calcium312$1,720
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$116$39,45239 claims
Boehringer IngelheimJardiance$19$37,47334 claims
Lilly USA, LLCTrulicity$103$36,55330 claims
PfizerEliquis, Abrysvo$15$26,36547 claims
GSKTrelegy Ellipta, Shingrix$29$23,67046 claims
AstraZenecaFarxiga$131$6,55211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,392 family providers in Indiana.

Other family in Milford

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →